FindTrial
Sign In

A study to capture the side effects and Quality of life(QoL) in castration-resistant prostate cancer patients who are receiving docetaxel as part of standard therapy in Tata Memorial Centre.

A prospective study to evaluate the Adverse Drug Reactions and to assess quality of life in prostate cancer patients receiving docetaxel in Tata Memorial Centre.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/09/021080
Enrollment
200
Registered
2019-09-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C61- Malignant neoplasm of prostate

Interventions

None listed

Sponsors

Tata Memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient of either gender aged 18 or more than 18 2. Metastatic Prostate Carcinoma patients receiving docetaxel chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Patient not willing to give consent. 2. Patients having non-compliance to the treatment schedule at Tata memorial Hospital or ACTREC.

Design outcomes

Primary

MeasureTime frame
Adverse Drug ReactionTimepoint: 2 Weekly- 3 Weekly—

Secondary

MeasureTime frame
Causality assessment of the adverse reactionsTimepoint: 2 Weekly- 3 Weekly;Grade III and Grade IV adverse eventsTimepoint: 2 Weekly- 3 Weekly;quality of lifeTimepoint: 2-3 Monthly—

Countries

India

Contacts

Public ContactDr Manjunath Nookala

Tata Memorial Hospital

dramitjoshi74@gmail.com9769331525

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026